“Our goal with THC and Project Varin is simple: delivering to the cannabis industry a better form of THC that is substantially more effective, less expensive, and free of the potentially dangerous chemicals used in currently available formulations. Over the past few months, our research program has made substantial progress toward these goals with strong successes in CBD, Tetrahydrocannabivarin (THC-V), and Cannabinol (CBN). By applying what we have learned thus far to THC, we hope to formulate an entirely new class of THC product for the cannabis industry that will be included under our nanotechnology provisional patent filing and future patent applications,” commented Company CEO,
The Company’s addition of THC to Project Varin will be performed in conjunction with
The use of nanotechnologies in the cannabis industry is not new, with many licensed dispensaries and delivery services offering products. Consumers often prefer the nano-enhanced version of products due to the increased psychoactive effect; such products, however, are expensive to manufacturer and are loaded with significant amounts of chemical surfactants, emulsifiers, and other additives, which may not be healthy and usually added very unpleasant flavors to foods and beverages. The Company’s technologies are designed to produce cannabinoids that offer vastly different properties that are free of surfactants, emulsifiers, and similar chemicals.
About Provisional Patent Filings
Psychoactive Cannabis and Federal Law
Psychoactive Cannabis containing more than 0.3% THC is a Schedule 1 controlled substance and is illegal under federal law, specifically the Controlled Substances Act (21 U.S.C. § 811). Even in states that have legalized the use of psychoactive cannabis for medical and/or recreational use, its sale and use remain violations of federal law. The illegality of psychoactive cannabis under federal law preempts state laws that legalize its use. Strict enforcement of federal law regarding psychoactive cannabis would materially impact our business.
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future
For more information, please contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabis-global-seeks-to-rewrite-thc-cost-and-bioavailability-via-inclusion-of-thc-under-provisional-patent-filed-nanotechnology-program-301155823.html